Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral Sclerosis
- PMID: 40781905
- DOI: 10.1002/ana.70025
Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral Sclerosis
Abstract
Objective: Tofersen is the first effective and approved therapy for superoxide dismutase 1 (SOD1)-associated amyotrophic lateral sclerosis (ALS [SOD1-ALS]). Following treatment with tofersen, neurofilament levels in patients' cerebrospinal fluid (CSF) and serum seem to respond earlier than clinical parameters. This evidence prompted us to hypothesize that this novel treatment could provide an opportunity to identify additional biomarkers responsive to therapy in SOD1-ALS.
Methods: We investigated a panel of 120 neural, glial, and inflammatory markers in CSF and serum samples longitudinally collected from a total of 28 SOD1-ALS patients at baseline, and after 3, 6 and 12 months of treatment with tofersen, followed by validation with conventional methodology.
Results: We identified a set of proteins, including neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40 and amyloid-beta 1-42, neuropeptide Y (NPY), and ubiquitin C-terminal hydrolase L1 (UCHL1), whose CSF levels both differed between SOD1-ALS and the control group, and were responsive to tofersen at 3 and 6 months after treatment initiation. Another group of markers, including the neuropentraxin (NPTX) family members NPTX1, NPTX2 and NPTXR, did not separate untreated SOD1-ALS from controls, but was responsive to tofersen. At 12 months on tofersen the levels of neurofilament light chain, neurofilament heavy chain, NPTX1, NPTX2, and NPTXR remained reduced compared with baseline, and correlated with the clinical response to tofersen. Consistent with increasing CSF pleocytosis and intrathecal immunoglobulin production, inflammatory markers were significantly increased after 12 months of treatment.
Interpretation: Our results highlight a complex, time-dependent differential response of CSF biomarkers to tofersen treatment, and may pave the way for developing a panel of responsive proteins to make biomarker endpoints more robust in clinical trials for SOD1-ALS and beyond. ANN NEUROL 2025.
© 2025 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
References
-
- Miller T, Cudkowicz M, Genge A, et al. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2022;387:1099–1110.
-
- Wiesenfarth M, Forouhideh‐Wiesenfarth Y, Elmas Z, et al. Clinical characterization of common pathogenic variants of SOD1‐ALS in Germany. J Neurol 2024;271:6667–6679. https://doi.org/10.1007/s00415-024-12564-1.
-
- Weishaupt JH, Körtvélyessy P, Schumann P, et al. Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients. Commun Med 2024;4:150. https://doi.org/10.1038/s43856-024-00573-0.
-
- Meyer T, Schumann P, Weydt P, et al. Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: treatment experience in clinical practice. Muscle Nerve 2023;67:515–521. https://doi.org/10.1002/mus.27818.
-
- Wiesenfarth M, Dorst J, Brenner D, et al. Effects of tofersen treatment in patients with SOD1‐ALS in a “real‐world” setting ‐ a 12‐month multicenter cohort study from the German early access program. EClinicalMedicine 2024;69:102495. https://doi.org/10.1016/j.eclinm.2024.102495.
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous